Cargando…
A novel signature to predict the neoadjuvant chemotherapy response of bladder carcinoma: Results from a territory multicenter real-world study
Background: Although neoadjuvant chemotherapy (NAC) has become the standard treatment option for muscle invasive bladder carcinoma (MIBC), its application is still limited because of the lack of biomarkers for NAC prediction. Methods: We conducted a territory multicenter real-world study to summariz...
Autores principales: | Li, Huihuang, Hu, Jiao, Zu, Xiongbing, Chen, Minfeng, Chen, Jinbo, Zou, Yihua, Deng, Ruoping, Qin, Gang, Li, Wenze, Tang, Jiansheng, Deng, Dingshan, Liu, Jinhui, Cheng, Chunliang, Cui, Yu, Ou, Zhenyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667090/ https://www.ncbi.nlm.nih.gov/pubmed/36406127 http://dx.doi.org/10.3389/fgene.2022.1047481 |
Ejemplares similares
-
Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study
por: Hu, Jiao, et al.
Publicado: (2022) -
BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti‐PD‐1/PD‐L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity
por: Cai, Zhiyong, et al.
Publicado: (2023) -
S100A5 Attenuates Efficiency of Anti‐PD‐L1/PD‐1 Immunotherapy by Inhibiting CD8(+) T Cell‐Mediated Anti‐Cancer Immunity in Bladder Carcinoma
por: Li, Huihuang, et al.
Publicado: (2023) -
Adjuvant chemotherapy in patients with locally advanced bladder cancer after neoadjuvant chemotherapy and radical cystectomy: a systematic review and pooled analysis
por: Cai, Zhiyong, et al.
Publicado: (2021) -
Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis
por: Cheng, Chunliang, et al.
Publicado: (2021)